Literature DB >> 8712721

Interferons inhibit EGF-stimulated cell growth and reduce EGF binding in human breast cancer cells.

F Iacopino1, G Ferrandina, G Scambia, P Benedetti-Panici, S Mancuso, G Sica.   

Abstract

CG-5 estrogen-sensitive human breast cancer cells contain specific Epidermal Growth Factor receptors (EGF-R, Kd = 0.09-0.17 nM) and respond to the mitogenic effect of EGF. The increase in cell proliferation has been observed starting with very low concentrations of EGF (10-12M) and was statistically significant at all doses. Nevertheless, cell growth stimulation was emphasized when cells were grown under stringent culture conditions. When cells were exposed to 100 IU/ml of natural beta-interferon (n beta-IFN) the binding of EGF to the cell membrane was reduced after 72 hours of treatment, while the exposure of CG-5 cells to 1000 IU/ml of n beta-IFN resulted in an EGF-R reduction which started after 48 hours and became statistically significant after 72-120 hours. If CG-5 cells were treated with 1000 IU/ml of recombinant alpha 2b-interferon (ra2b-IFN) this reduction was observed after 168 hours of exposure to the drug. Both the IFNs abolished EGF-stimulated cell growth. Our results indicate that IFN treatment down-regulates EGF-R in estrogen-sensitive breast cancer cells and suggests that this down-regulation may be involved in the inhibitory action of IFN on cell growth.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8712721

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.

Authors:  Jian-Hua Ma; Emilia Patrut; Jan Schmidt; Hanns-Peter Knaebel; Markus W Büchler; Angela Märten
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

2.  Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach.

Authors:  A Albini; C Marchisone; F Del Grosso; R Benelli; L Masiello; C Tacchetti; M Bono; M Ferrantini; C Rozera; M Truini; F Belardelli; L Santi; D M Noonan
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

3.  Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma.

Authors:  Svetlana Karakhanova; Beate Mosl; Sabine Harig; Katharina von Ahn; Jasmin Fritz; Jan Schmidt; Dirk Jäger; Jens Werner; Alexandr V Bazhin
Journal:  Int J Mol Sci       Date:  2014-03-07       Impact factor: 5.923

4.  Interferon-α Promotes the Expression of Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma.

Authors:  Hailong Ma; Shufang Jin; Wenyi Yang; Zhuowei Tian; Shuli Liu; Yang Wang; Ge Zhou; Mei Zhao; Shalva Gvetadze; Zhiyuan Zhang; Jingzhou Hu
Journal:  J Cancer       Date:  2017-07-22       Impact factor: 4.207

Review 5.  Toll-like Receptors from the Perspective of Cancer Treatment.

Authors:  Nasir Javaid; Sangdun Choi
Journal:  Cancers (Basel)       Date:  2020-01-27       Impact factor: 6.639

6.  Interferon-α Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 Signaling.

Authors:  Alexandr V Bazhin; Katharina von Ahn; Jasmin Fritz; Jens Werner; Svetlana Karakhanova
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.